CLDN1

Across TCGA pan-cancer cohorts, CLDN1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CLDN1 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CLDN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLDN1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, UCEC, and SKCM are the cancer types where CLDN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	36	view →
UCEC	OS	Median	All	1.000	0.649	.009	22	view →
SKCM	DFS	Median	II,III,IV	0.984	0.551	.002	19	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CLDN1–BLCA (OS)

Open the BLCA breakdown →